Usted está aquí

Inicio / 1%

SAFETY AND EFFECTIVENESS OF NIMOTUZUMAB IN HIGH GRADE GLIOMA PATIENTSPHASE IV STUDY RESULTS.

Switch maintenance therapy with racotumomab ot nimotuzumab vs docetaxel for NCSLC patients

SAFETY AND EFFECTIVENESS OF NIMOTUZUMAB IN HIGH GRADE GLIOMA PATIENTSPHASE IV STUDY RESULTS.

Phosphocholine-Specific Antibodies Improve T-Dependent Antibody Responses against OVA Encapsulated into Phosphatidylcholine-Containing Liposomes

P3, a monoclonal antibody capable to activate B-1a cells

Use of Nimotuzumab in The Treatment of Locally Advanced EsophageaCancer in Real World

Economic evaluation of nimotuzumab treatment for head and neck cancer in Cuba.

Quantification of the Vi polysaccharide in the VaxTyVi ™ typhoid vaccine vaccine by sandwich ELISA using a monoclonal antibody

Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab.

Por: Current Drug Targets, 2016, 17, 666-677. IF= 1.55/Internacional/2016

REVISIÓN SISTEMÁTICA DE LOS MÉTODOS DE IMPUTACIÓN DE DATOS FALTANTES. EXPERIENCIAS EN LA MODELACIÓN DE LA TOMA DE DECISIONES EN LA SALUD HUMANA, MEDIO AMBIENTE Y DESARROLLO HUMANO.

Páginas

Pizarra
53-7-2717933
Dirección general
53-7-2714335
cim@cim.sld.cu
Calle 15 esq. 216 S/N, Siboney, Playa, La Habana, Cuba. A.P 16040, La Habana 11600, Cuba.
Código Postal:
11 600
Apartado Postal:
16 040